save and improve the lives of patients
learn moreawareness
There is an outstanding need for new treatments for bladder cancer. We are proud to support the Bladder Cancer Advocacy Network in building awareness of the need for a cure.
results
Our preliminary Phase 3 data show Vicineum™ is well-tolerated and demonstrates efficacy in patients with high-grade NMIBC.
innovation
Vicineum is a targeted fusion protein designed to overcome the fundamental efficacy and safety challenges inherent in existing antibody-drug conjugates.
bringing new hope for treating bladder cancer
Vicineum is our novel, lead product candidate that we hope will change the treatment landscape for patients with high-grade, non-muscle invasive bladder cancer (NMIBC).
LEARN MORE
BLADDER CANCER
6th
most common cancer
72
average age of diagnosis
80,000+
new cases each year in the U.S.
$4 billion
annual costs